Randrian Violaine, Evrard Camille, Tougeron David
Gastroenterology and Hepatology Department, Poitiers University Hospital, 86000 Poitiers, France.
Faculty of Medicine and Pharmacy, 86000 Poitiers, France.
Cancers (Basel). 2021 Jun 19;13(12):3063. doi: 10.3390/cancers13123063.
A defect in the DNA repair system through a deficient mismatch repair system (dMMR) leads to microsatellite instability (MSI). Microsatellites are located in both coding and non-coding sequences and dMMR/MSI tumors are associated with a high mutation burden. Some of these mutations occur in coding sequences and lead to the production of neo-antigens able to trigger an anti-tumoral immune response. This explains why non-metastatic MSI tumors are associated with high immune infiltrates and good prognosis. Metastatic MSI tumors result from tumor escape to the immune system and are associated with poor prognosis and chemoresistance. Consequently, immune checkpoint inhibitors (ICI) are highly effective and have recently been approved in dMMR/MSI metastatic colorectal cancers (mCRC). Nevertheless, some patients with dMMR/MSI mCRC have primary or secondary resistance to ICI. This review details carcinogenesis and the mechanisms through which MSI can activate the immune system. After which, we discuss mechanistic hypotheses in an attempt to explain primary and secondary resistances to ICI and emerging strategies being developed to overcome this phenomenon by targeting other immune checkpoints or through vaccination and modification of microbiota.
DNA修复系统中的缺陷,通过错配修复缺陷系统(dMMR)导致微卫星不稳定(MSI)。微卫星位于编码和非编码序列中,dMMR/MSI肿瘤与高突变负荷相关。其中一些突变发生在编码序列中,导致新抗原的产生,能够触发抗肿瘤免疫反应。这就解释了为什么非转移性MSI肿瘤与高免疫浸润和良好预后相关。转移性MSI肿瘤是肿瘤逃避免疫系统的结果,与预后不良和化疗耐药相关。因此,免疫检查点抑制剂(ICI)非常有效,最近已被批准用于dMMR/MSI转移性结直肠癌(mCRC)。然而,一些dMMR/MSI mCRC患者对ICI有原发性或继发性耐药。本综述详细介绍了致癌作用以及MSI激活免疫系统的机制。之后,我们讨论了机制假说,试图解释对ICI的原发性和继发性耐药,以及正在开发的通过靶向其他免疫检查点或通过疫苗接种和改变微生物群来克服这一现象的新策略。